Bank of New York Mellon Corp Has $1.80 Million Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Bank of New York Mellon Corp increased its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 4.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 121,250 shares of the company’s stock after purchasing an additional 5,409 shares during the period. Bank of New York Mellon Corp owned approximately 0.34% of iTeos Therapeutics worth $1,799,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Quest Partners LLC bought a new position in iTeos Therapeutics during the 4th quarter valued at $90,000. China Universal Asset Management Co. Ltd. grew its holdings in iTeos Therapeutics by 66.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,877 shares of the company’s stock valued at $94,000 after buying an additional 2,737 shares in the last quarter. Aristides Capital LLC purchased a new position in iTeos Therapeutics during the 4th quarter valued at about $157,000. Los Angeles Capital Management LLC purchased a new position in shares of iTeos Therapeutics during the first quarter worth about $401,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of iTeos Therapeutics by 66.3% during the fourth quarter. Russell Investments Group Ltd. now owns 39,508 shares of the company’s stock worth $433,000 after purchasing an additional 15,757 shares in the last quarter. 97.16% of the stock is currently owned by institutional investors.

iTeos Therapeutics Price Performance

NASDAQ:ITOS opened at $11.59 on Thursday. iTeos Therapeutics, Inc. has a 1-year low of $8.20 and a 1-year high of $18.75. The business has a 50 day moving average of $16.12 and a 200 day moving average of $14.63. The company has a market capitalization of $418.67 million, a price-to-earnings ratio of -3.07 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.86. The company had revenue of $35.00 million during the quarter, compared to the consensus estimate of $4.20 million. As a group, sell-side analysts anticipate that iTeos Therapeutics, Inc. will post -4.21 EPS for the current year.

Wall Street Analyst Weigh In

ITOS has been the subject of several recent analyst reports. Wedbush reissued an “outperform” rating and set a $21.00 price objective on shares of iTeos Therapeutics in a report on Thursday, August 8th. JPMorgan Chase & Co. dropped their target price on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a research report on Monday. Finally, Wells Fargo & Company began coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 target price for the company.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.